Blog Read the latest perspectives from our team of subject matter experts and others Defacto Health Joins H1When we started Defacto Health, we set out to solve a single problem: the industry had no way of knowing which providers were in which payers’ networks. At best, providers… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology Artificial IntelligenceBalancing Creativity and Accuracy in Artificial IntelligenceIn the realm of AI, balancing creativity and accuracy is a critical consideration, especially when developing AI systems for business applications. While creativity adds novelty and innovation to outputs,… Continue reading → Read the articleno CommercializationDrug DevelopmentWhat Payer Trends Can Tell Us About Medication AdherenceOne thing the healthcare ecosystem lacks in the United States is a system of shareable, actionable healthcare data. So where is one possible place pharma can look for insights… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationImproving Oncology Clinical Trials for Accelerated ApprovalIn March of 2023, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design specific… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationWhy Drug Approvals and Development Hinge on DiversityThe success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within… Continue reading → Read the articleno Drug DevelopmentKOL EngagementPatient RepresentationBuilding an Exclusive Strategy with Inclusive HCPsAs healthcare providers (HCPs) are increasingly relying on evidence-based data and clinical guidelines, life science organizations must shift their focus to enabling HCPs in the effective adoption of these medicines.… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationFour Strategies for Preparing FDA DAPsIn the race to bring new treatments and cures to market, clinical trial operations and feasibility teams often face a formidable challenge: ensuring that patient populations are accurately represented… Continue reading → Read the articleno«‹78910111213›»
